2020 TTF AM Q&A Panel - Molecular Profiling, Broad Gene Testing, RNA Testing, and Liquid Biopsies

dbrock's picture
2020 Targeted Therapies Patient Forum, AM Question & Answer Panel: The Advantages or Downfalls to Molecular Profiling and Broad Gene Testing, RNA Testing, and Liquid Biopsies
H. Jack West, MD, Founder, President and CEO
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

Access to the full agenda can be found here: https://bit.ly/39131em

Full bios for attending faculty can be found here: https://bit.ly/2M0FVLH

 
In this video from the AM Question and Answer Session of the event, Drs. West, Raez, Weiss and Janne discuss the advantages or downfalls to molecular profiling and broad gene testing, RNA testing and liquid biopsies.

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language: 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation